{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:41:08Z","timestamp":1746718868007},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T00:00:00Z","timestamp":1387065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00277-013-1989-5","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T05:49:52Z","timestamp":1387000192000},"page":"797-802","source":"Crossref","is-referenced-by-count":12,"title":["Relationship between the 46\/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis"],"prefix":"10.1007","volume":"93","author":[{"given":"Alejandra","family":"Mart\u00ednez-Trillos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,15]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372\u2013375","journal-title":"Blood"},{"key":"1989_CR2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"1989_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"1989_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"1989_CR5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"1989_CR6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferrative neoplasms. Nat Genet 41:446\u2013449","journal-title":"Nat Genet"},{"key":"1989_CR7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, Harutyunyan A, J\u00e4ger R et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450\u2013454","journal-title":"Nat Genet"},{"key":"1989_CR8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","volume":"41","author":"O Kilpivaara","year":"2009","unstructured":"Kilpivaara O, Mukherjee S, Schram AM et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455\u2013459","journal-title":"Nat Genet"},{"key":"1989_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Patnaik MM et al (2010) JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival. Leukemia 24:105\u2013109","journal-title":"Leukemia"},{"key":"1989_CR10","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2013.21","volume":"27","author":"J Wang","year":"2013","unstructured":"Wang J, Xu Z, Liu L et al (2013) JAK2V617F allele burden, JAK2 46\/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia 27:1763\u20131767","journal-title":"Leukemia"},{"key":"1989_CR11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2010.126","volume":"24","author":"P Guglielmelli","year":"2010","unstructured":"Guglielmelli P, Biamonte F, Spolverini A et al (2010) Frequency and clinical correlates of JAK2 46\/1 (GGCC) haplotype in primary myelofibrosis. Leukemia 24:1533\u20131537","journal-title":"Leukemia"},{"key":"1989_CR12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097","journal-title":"Blood"},{"key":"1989_CR13","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","volume":"13","author":"J Thiele","year":"1999","unstructured":"Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R (1999) Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)\u2014a clinicopathological study. Leukemia 13:1741\u20131748","journal-title":"Leukemia"},{"key":"1989_CR14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D et al (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60\u201370","journal-title":"Blood"},{"key":"1989_CR15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.leu.2404915","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:438\u2013439","journal-title":"Leukemia"},{"key":"1989_CR16","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20133001","journal-title":"Blood"},{"key":"1989_CR17","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"G Wernig","year":"2006","unstructured":"Wernig G, Mercher T, Okabe R et al (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274\u20134281","journal-title":"Blood"},{"key":"1989_CR18","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2003-03-0885","volume":"102","author":"R Kralovics","year":"2003","unstructured":"Kralovics R, Stockton DW, Prchal JT (2003) Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102:3793\u20133796","journal-title":"Blood"},{"key":"1989_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","volume":"108","author":"I Bellann\u00e9-Chantelot Chaumarel","year":"2006","unstructured":"Bellann\u00e9-Chantelot Chaumarel I, Labopin M et al (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108:346\u2013352","journal-title":"Blood"},{"key":"1989_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ng0409-385","volume":"41","author":"PJ Campbell","year":"2009","unstructured":"Campbell PJ (2009) Somatic and germline genetics at the JAK2 locus. Nat Genet 41:385\u2013386","journal-title":"Nat Genet"},{"key":"1989_CR21","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2009.110","volume":"23","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, Skoda RC, Looser R et al (2009) The \u2018GGCC\u2019 haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924\u20131926","journal-title":"Leukemia"},{"key":"1989_CR22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lasho TL, Finke CM et al (2010) The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status\u2014clinical correlates in a study of 226 consecutive patients. Leukemia 24:110\u2013114","journal-title":"Leukemia"},{"key":"1989_CR23","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","volume":"115","author":"AV Jones","year":"2010","unstructured":"Jones AV, Campbell PJ, Beer PA et al (2010) The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115:4517\u20134523","journal-title":"Blood"},{"key":"1989_CR24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/leu.2010.1","volume":"24","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Lasho TL, Finke CM et al (2010) MPL mutation effect on JAK2 46\/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 24:859\u2013860","journal-title":"Leukemia"},{"key":"1989_CR25","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","volume":"30","author":"F Cervantes","year":"2012","unstructured":"Cervantes F, Dupriez B, Passamonti F et al (2012) Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 30:2981\u20132987","journal-title":"J Clin Oncol"},{"key":"1989_CR26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi A et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the International Working Group for Myeloproliferative Neoplasms Research and Treatment. Blood 115:1703\u20131708","journal-title":"Blood"},{"key":"1989_CR27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Pardanani A, Hanson CA et al (2011) DIPSS-Plus: a refined dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 29:392\u2013397","journal-title":"J Clin Oncol"},{"issue":"9","key":"1989_CR28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861\u20131869","journal-title":"Leukemia"},{"key":"1989_CR29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J et al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:756\u2013761","journal-title":"Leukemia"},{"key":"1989_CR30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G et al (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114:1477\u20131483","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1989-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1989-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1989-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T03:39:29Z","timestamp":1597203569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1989-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1989-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]}}}